OBJECTIVE： To investigate the effects of neoadjunctive chemotherapy （NAC） of docetaxel and epirubicin combined with cyclophosphamide on clinical efficacy and tumor markers of breast cancer patients with different molecular types. METHODS： A total of 88 female patients with locally advanced breast cancer collected from our hospital during Jan. 2014-Jan. 2016 were divided into Luminal A type （23 cases）， Luminal B type （21 cases）， basal-like type （11 cases）， HER2-over expressing type （18 cases） and normal breast-like type （15 cases） according to molecular type. All patients were given Docetaxel injection+Epirubicin hydrochloride injection+Cyclophosphamide for injection for consecutive 6 cycles （21 d as a cycle）. Total response rates and pathological complete remission （pCR） rates were compared among breast cancer patients with different molecular types. The expression of serum tumor markers [CEA， CA125， CA153] were compared before and after treatment， and the occurrence of ADR was recorded. RESULTS： Total response rate of 88 patients was 63.64％， among which that of basal-like breast cancer patients was 72.73％， significantly higher than other molecular types， with statistical significance （P＜0.05）. There was no statistical significance in total response rates of pairwise molecular type comparison （P＞0.05）. The pCR rate of 88 patients was 27.27％， and that of basal-like breast cancer patients was the highest （45.45％）. There was statistical significance in pCR rates of pairwise molecular type comparison （P＜0.05）， except there was no significant difference in pCR rate between HER2-over expressing type and normal breast-like type （P＞0.05）. Before treatment， there was no statistical significance in the expression of CEA， CA125 and CA153 in breast cancer patients with different molecular types （P＞0.05）. After treatment， the expression of CEA， CA125 and CA153 in different molecular types were decreased significantly， with statistical significance （P＜0.05）. There was no statistical significance in the expression of above markers among different molecular types （P＞0.05）. There was no statistical significance in the incidence of ADR among different molecular types （P＞0.05）. CONCLUSIONS： NAC plan of docetaxel and epirubicin combined with cyclophosphamide can reduce the expression of tumor markers and shows certain therapeutic efficacy for breast cancer patients with different molecular types. Total response rate and pCR rate of basal-like type are better than those of other molecular types， so NAC plan is the preferred treatment for basal-like type breast cancer.